Theme stage · accelerating
Gene therapy and rare-disease stocks to watch.
As of 11 November 2026
Viridian Therapeutics' Lumvoa launch beat estimates and positive VRDN-008 data on 9 November 2026 add an autoimmune franchise.
Xeris Biopharma's Recorlev sales rose 93% to $71.5 million in the third quarter, and 2026 revenue guidance rose to $395-405 million.
Research view: likely to lag the S&P 500. Precision BioSciences' hepatitis B gene-editing data held up in full, but with no clinical result due before Phase 2 dosing in early 2027 the shares are more likely to lag the S&P 500.
Septerna's oral-drug pipeline faces its test in Q1 2027, when SEP-479 Phase 1 liver-safety data are due; after a Q3 revenue miss, the $52.34 trailing-year high close on 10 November 2026 already assumes a clean result.
"3-mo price move" is the stock's market price change, not a FrontierPicks return. The "3-mo price move" column is one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it.
How this page is built
These are the names FrontierPicks researches in the gene therapy and rare-disease stocks theme, each with a dated research note. Names in the latest top-50 momentum scan come first, ordered by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closing prices, through the last completed session; the rest follow by the research's conviction, highest first. The research decides which stocks belong to each theme; this one currently reads as accelerating: attention and buyers are arriving.
Questions
- What gene therapy and rare-disease stocks does FrontierPicks cover?
- As of 11 November 2026, the gene therapy and rare-disease stocks FrontierPicks researches are led by VRDN, XERS, DTIL, SEPN, each with a dated research note. Names in the latest top-50 momentum scan come first, ordered by composite momentum score; the rest follow by the research's conviction, highest first.
- Is the gene therapy and rare-disease stocks theme accelerating or slowing?
- FrontierPicks reads this theme as accelerating (attention and buyers are arriving) as of 11 November 2026. Developers of rare- and specialty-disease drugs are rising on trial data and new analyst coverage. Viridian Therapeutics (VRDN) reported positive VRDN-008 results supporting dosing every eight weeks on 9 November 2026, and Precision BioSciences (DTIL) reported positive Phase 1 data for its hepatitis B gene-editing treatment the same day. Guggenheim started covering Disc Medicine (IRON) with a Buy rating and a $132 target. The narrative is still accelerating: Wedbush raised its Viridian target to $44 and Wells Fargo raised it to $39 on 10 November 2026, while companies sell stock into the rally — Precision announced a $125 million offering on 6 November 2026, and Disc set up an at-the-market sale of up to $189.93 million on 5 November 2026. Disc Medicine and Septerna (SEPN) join this week.
- How does FrontierPicks rank gene therapy and rare-disease stocks?
- Names in the latest top-50 momentum scan come first, ordered by composite momentum score; the rest follow by the research's conviction, highest first. The full method is on the methodology page.
Related
As of 11 November 2026